NASDAQ:HSIC - Henry Schein Stock Price, News, & Analysis

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Henry Schein's stock split on the morning of Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly minted shares were issued to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein announced that its Board of Directors has initiated a share buyback program on Thursday, December 13th 2018, which allows the company to buyback $400,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to buy up to 3.1% of its shares through open market purchases. Shares buyback programs are generally an indication that the company's board of directors believes its shares are undervalued.

Henry Schein, Inc. (NASDAQ:HSIC) issued its quarterly earnings results on Tuesday, November, 6th. The company reported $1.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.01 by $0.02. The company had revenue of $3.28 billion for the quarter, compared to analyst estimates of $3.37 billion. Henry Schein had a net margin of 3.00% and a return on equity of 20.40%. The company's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.87 EPS. View Henry Schein's Earnings History.

Henry Schein is scheduled to release their next quarterly earnings announcement on Tuesday, February 19th 2019. View Earnings Estimates for Henry Schein.

Henry Schein issued an update on its FY18 earnings guidance on Tuesday, November, 6th. The company provided earnings per share (EPS) guidance of $4.06-4.14 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.12.

16 analysts have issued 1 year target prices for Henry Schein's shares. Their forecasts range from $66.00 to $102.00. On average, they anticipate Henry Schein's share price to reach $85.6429 in the next year. This suggests a possible upside of 6.4% from the stock's current price. View Analyst Price Targets for Henry Schein.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 2 sell ratings, 6 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Henry Schein.

Media stories about HSIC stock have trended somewhat positive recently, according to InfoTrie. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Henry Schein earned a news impact score of 1.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Some companies that are related to Henry Schein include Illumina (ILMN), Celgene (CELG), Zoetis (ZTS), HCA Healthcare (HCA), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Humana (HUM), Baxter International (BAX), Edwards Lifesciences (EW), Actelion (ALIOF), ASTELLAS PHARMA/ADR (ALPMY), ESSILOR Intl S/S (ESLOY), Takeda Pharmaceutical (TKPYY), FRESENIUS SE &/S (FSNUY) and Centene (CNC).

Henry Schein's stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc (10.67%), Longview Partners Guernsey LTD (8.92%), BlackRock Inc. (6.94%), FMR LLC (5.69%), Select Equity Group L.P. (4.08%) and Brown Brothers Harriman & Co. (3.40%). Company insiders that own Henry Schein stock include Barry J Alperin, David Mckinley, Donald J Kabat, Gerald A Benjamin, James A Harding, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy, Stanley M Bergman and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Mackenzie Financial Corp, Deutsche Bank AG, Alecta Pensionsforsakring Omsesidigt, Select Equity Group L.P., Brown Brothers Harriman & Co., Schroder Investment Management Group and JPMorgan Chase & Co.. Company insiders that have sold Henry Schein company stock in the last year include David Mckinley, Mark E Mlotek, Michael S Ettinger, Paul Brons, Stanley M Bergman and Steven Paladino. View Insider Buying and Selling for Henry Schein.

HSIC stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Atlanta Capital Management Co. L L C, Morgan Stanley, AXA, American Century Companies Inc., WINTON GROUP Ltd, Ancora Advisors LLC and First Trust Advisors LP. View Insider Buying and Selling for Henry Schein.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HSIC stock can currently be purchased for approximately $80.52.

Henry Schein has a market capitalization of $12.27 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe.

The official website for Henry Schein is http://www.henryschein.com.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]